The JAK inhibitor ‘Olumiant’ may be prescribed to treat hair loss in Korea within the year.

According to industry sources, the Ministry of Food and Drug Safety is conducting a review on expanding the indication of Lilly Korea’s JAK inhibitor Olumiant (baricitinib) to severe alopecia areata in Korea. The company may receive the final marketing authorization for the indication in the first half of the year at the earliest.

Olumiant was approved for the alopecia areata indication in the US and Japan in June last year and received a recommendation for its use in the EU as well. With the approvals, the drug is quickly making its way into the global market.

Olumiant selective